The Business of Biologics

PharmaVoice
September 2018
Featuring: David Balderson, Sciformix – A Covance Company

Since the first recombinant DNA product was approved in 1982 — Humulin developed by Genentech and marketed by Lilly — biologics have brought tremendous innovation and medical benefits to patients. More than 35 years later, the biopharma industry continues to innovate as scientific and medical knowledge advances.

Biologics — large molecule drugs typically derived from living cells — have had an enormous impact. To date, more than 250 biologic therapies and vaccines have transformed the lives of hundreds of millions of patients. Once debilitating diseases have been drastically modified, and newer therapies are being developed for once life-threatening diseases. Over the last 15 years, there has been a gradual shift of investment dollars from small-molecule drugs to biologics.

Read the full article here.